Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study

Last updated: July 8, 2025
Sponsor: Wayne State University
Overall Status: Completed

Phase

1

Condition

Post-traumatic Stress Disorders

Treatment

Placebo capsule

Dronabinol 7.5 milligram oral capsule

Clinical Study ID

NCT04080427
R33MH111935
R61MH111935
  • Ages 18-60
  • All Genders

Study Summary

The goal of this study is to look at how a type of drug called cannabinoids are related to the processing of fear signals, the experience of emotions and fear, and the pattern of activity in the brain that is involved in these processes and how this relates to the treatment of post-traumatic stress disorder (PTSD). PTSD is an anxiety disorder that occurs after experiencing a traumatic event(s) and is characterized by unwanted memories of the trauma(s) through flashbacks or nightmares, avoidance of situations that remind the person of the event, difficulty experiencing emotions, loss of interest in activities the person used to enjoy, and increased arousal, such as difficulty falling asleep or staying asleep, anger and hypervigilance. The information gained from this study could lead to the development of new treatments for persons who suffer from anxiety or fear-based disorders.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Between ages 18-60

  • Willing and able to consent to study

  • Generally medically and neurologically healthy (including no evidence ofintellectual disability or serious cognitive impairment that would interfere withtask performance)

  • Exposure to Criterion A stressor defined by CAPS-5 and identified by Life EventsChecklist-5 (LEC-5)

  • Significant PTSD severity as indicated by CAPS-5 diagnosis and/or score >= 25 of atleast one month prior to study entry, PTSD is patient's primary concern

Exclusion

Exclusion Criteria:

  • Positive urine pregnancy test prior to fMRI, self-reported current pregnancy duringscreening, or planning pregnancy

  • Currently breastfeeding/ lactating

  • MRI contraindications (e.g., ferrous metal in head/body)

  • Pervasive development disorder history

  • Traumatic brain injury (TBI) with current cognitive impairment related to TBI

  • Risk of harm to self or others that requires immediate intervention

  • Presence of contraindications, current or past allergic or adverse reaction, orknown sensitivity to cannabinoid-like substances (dronabinol/marijuana/cannabis/THC,cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)

  • Lack of fluency in English

  • Inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia

  • Exclusively left-handed (score of -100 on Handedness Questionnaire)

  • Current or past diagnosis of bipolar, schizophrenia spectrum, psychotic and relateddisorders

  • Current severe alcohol or substance use

  • Comorbid mood or anxiety disorder that is primary to PTSD

  • Concomitant treatment with medication taken daily that has level 1 evidenceindicating severe drug-drug interactions with dronabinol

Study Design

Total Participants: 102
Treatment Group(s): 2
Primary Treatment: Placebo capsule
Phase: 1
Study Start date:
April 15, 2021
Estimated Completion Date:
May 31, 2025

Study Description

The total time commitment estimated per participant 18 study visits. This is broken down below:

Visit 1: Questionnaires, Screening, and Orientation: During this visit the potential participant will learn about the study procedures, sign the informed consent documents, and fill out a packet of forms that ask about his or her race and ethnic background, use of drugs and alcohol and physical and mental health.

Visit 2: Pre-Treatment Behavioral Tests and and Magnetic Resonance (MR) Scan: During this visit the participant will complete several computer tasks, and the study staff will be measuring reaction time and psychophysiological measures.The tasks that the participant will perform will show three different images and an aversive stimulus (e.g. loud burst of noise or animated snake) may follow one image most of the time, while the other images may never be followed by the aversive cue. The participant will need to try to predict whether the aversive cue will occur or not based on which image is shown and will be asked to repeatedly rate on a scale how likely it is that he or she thinks an aversive cue will occur after each image. Lastly, during the session the participant will also be asked to report his or her level of anxiety on a scale from 0 to 100.

Visit 3: Pre-Treatment Behavioral Tests and MR Scan: This visit will be very similar to Visit 2. Participants will participate in the same type of task inside the MR scanner, while the study staff measures reaction time and psychophysiological responding and brain activation. Participants will view the same images he or she did previously, and may experience the same aversive stimulus as during Visit 2. Participants will again be asked to rate how much they expect to experience the aversive stimulus after each image and will also be asked to report their level of anxiety on a scale from 0 to 100.

Visits 4 & 5: Prolonged Exposure (PE) Sessions 1 & 2: These sessions will consist of psychoeducation that includes discussion or reactions to trauma , treatment rationale, breathing retraining, and review of SUDS to assess level of distress from 0 to 100 (100=extreme anxiety/distress) when facing fears. One session occurs weekly across 2 weeks.

Visits 6-14: PE Sessions 3-11: These sessions will consist of repeated exposures to trauma memories (imaginal exposure) and avoided situations (in vivo exposure). As is standard, patients will also practice exposures (e.g., listen to tapes of imaginal exposure, carry out in vivo exposure) outside of PE sessions as "homework". At exposure-focused sessions (Sessions 3-11) either THC or PBO will be administered just before the session. One session occurs weekly across 8 weeks.

Visit 15: PE Session 12 [Post-treatment Assessment]: This session will include a review of therapeutic gains/relapse prevention/assessments.

Visit 16: Post-Treatment Behavioral Tests and MR Scan: This visit will be very similar to Visit 2. Participants will participate in the same type of task inside the MR scanner, while the study staff measures reaction time and psychophysiological responding and brain activation. Participants will view the same images he or she did previously, and may experience the same aversive stimulus as during Visit 2. Participants will again be asked to rate how much they expect to experience the aversive stimulus after each image and will also be asked to report their level of anxiety on a scale from 0 to 100.

Visit 17: Post-Treatment Behavioral Tests and MR Scan: This visit will be very similar to Visit 3. Participants will participate in the same type of task inside the MR scanner, while the study staff measures reaction time and psychophysiological responding and brain activation. Participants will view the same images he or she did previously, and may experience the same aversive stimulus as during Visit 3. Participants will again be asked to rate how much they expect to experience the aversive stimulus after each image and will also be asked to report their level of anxiety on a scale from 0 to 100.

Visit 18: 3-Month Follow-Up Treatment Assessment: This session is similar to Visit 15 and will include review of therapeutic gains/relapse prevention/assessments.

Connect with a study center

  • Eugene Applebaum College of Pharmacy and Health Sciences

    Detroit, Michigan 48201
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.